Archean Chemical Q1 FY27: Revenue up, margins lag

Results announcement and why it matters

Archean Chemical Industries Limited reported unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27). The Board of Directors considered and approved the results on July 30, 2026, and the company stated that the unaudited results were reviewed by the Audit Committee. A limited review report from the statutory auditors was enclosed with an unmodified conclusion.

For investors tracking chemical and specialty chemical names, the quarter stood out for two reasons. First, revenue held up, with multiple disclosures pointing to year-on-year growth in revenue from operations. Second, profitability looked mixed when compared with the same period last year, but it rebounded sharply from the immediately preceding quarter as per the company’s summary metrics.

The numbers below include both standalone and consolidated disclosures in ₹ crore to keep the presentation comparable across statements that use lakhs, million, and crore.

Standalone performance: income up, profits lower YoY

For the quarter ended June 30, 2026, standalone total income from operations was ₹315.93 crore. Including other income, standalone total income was ₹332.07 crore.

Standalone total expenses for the quarter were ₹276.76 crore, leading to a standalone profit before tax (PBT) of ₹55.31 crore. After a standalone tax expense of ₹14.79 crore, the standalone profit after tax (PAT) was ₹40.53 crore. The company also reported standalone total comprehensive income of ₹40.44 crore.

Standalone earnings per share (basic and diluted) for Q1 FY27 were reported at ₹3.28. Separately, a market snapshot in the provided data set noted that standalone revenue from operations increased to ₹315.93 crore in Q1 FY27 compared with ₹278.63 crore in Q1 FY26, while standalone PAT declined to ₹40.53 crore from ₹51.85 crore over the same period.

Consolidated performance: income stable, PAT lower YoY but better QoQ

On a consolidated basis, total income from operations for Q1 FY27 was ₹327.20 crore. Total consolidated income, including other income, was ₹332.81 crore, while total consolidated expenses were ₹288.59 crore.

This translated into consolidated PBT of ₹44.22 crore and a consolidated tax expense of ₹13.86 crore. Consolidated PAT for the quarter was ₹30.35 crore, and consolidated total comprehensive income was ₹30.27 crore. Consolidated basic and diluted EPS was reported at ₹2.48.

The company’s result summary shared alongside the filing also listed consolidated revenue at ₹327.20 crore, EBITDA at ₹67.26 crore, and PAT at ₹30.35 crore for Q1 FY27. It further highlighted a strong sequential recovery versus Q4 FY26 across EBITDA, PBT, and PAT, even as year-on-year profitability remained under pressure.

EBITDA and margins: sequential rebound, YoY pressure

In the result summary, EBITDA for Q1 FY27 was ₹67.26 crore. The summary indicated a year-on-year decline of 13.87% but a quarter-on-quarter increase of 53.94%.

EBITDA margin was reported at 20.56% for Q1 FY27. This was lower than 26.71% in the year-ago quarter but improved from 14.52% in Q4 FY26, as per the same summary.

Profit before tax was listed at ₹44.22 crore in the summary, down 23.77% year-on-year and up 178.89% quarter-on-quarter. PAT was listed at ₹30.35 crore, down 24.38% year-on-year and up 148.24% quarter-on-quarter. The summary also included PAT after minority interest at ₹30.68 crore, down 23.67% year-on-year and up 128.61% quarter-on-quarter.

Other income and what it signals

Other income in the Q1 FY27 summary was ₹5.61 crore, versus ₹8.23 crore in the year-ago quarter and ₹5.39 crore in Q4 FY26. In the standalone statement, the gap between income from operations (₹315.93 crore) and total income (₹332.07 crore) also reflects the role of other income during the quarter.

While the provided text does not break down the components of other income, the reported year-on-year drop suggests that non-operating contributions were lower than the prior-year quarter. This matters because margins and profit comparisons become more dependent on operating efficiency when other income is softer.

Key corporate events: call schedule, dividend, and pledge release

Archean Chemical scheduled an earnings conference call for August 3, 2026, at 11:00 AM IST to discuss Q1 FY27 performance. Management participation listed for the call included Managing Director Rampraveen Swaminathan and CFO Natarajan Ramamurthy, with DGM Finance Rajeev Kumar also named.

The company had recommended a final dividend of ₹2.50 per equity share for FY26. June 5, 2026 was fixed as the record date, and payment was completed on or before July 11, 2026, as stated in the provided update.

The same data set also noted a promoter pledge release of 2.2 million shares on July 6, 2026, described as about 1.7% of equity.

Expansion and risk flags mentioned in the update

One update in the provided text cited a subsidiary investment of ₹170 crore in Acume Chemicals on June 17, 2026. The same section flagged a pending land lease renewal, noting that the land lease expiry date was July 31, 2018, and that a renewal application was pending.

The broader context in the provided material also mentioned bromine production expectations, stating that production is expected to grow by 15%-20% annually, with a plan to move from about 20,000 tons to 25,000 tons next year, and eventually to 40,000 tons over time. The text also stated that the transcript did not mention any current or planned fundraising through debt or equity.

Market snapshot indicators cited in the dataset

The provided content included two market snapshots: one listing price at ₹535 with market cap at about ₹6.6K crore and a P/E ratio of 62.1, and another listing price at ₹567 with market cap at ₹7,004 crore. These figures were presented without a common timestamp in the text, so they should be read as indicative snapshots rather than a single point-in-time quote.

Summary table of reported Q1 FY27 numbers (₹ crore)

Timeline and key disclosed events

Market impact: what the quarter signals from disclosed data

From the disclosed metrics, the clearest pattern is a sequential recovery in profitability from Q4 FY26 alongside a weaker year-on-year comparison in margins. The summary metrics showed EBITDA margin improving to 20.56% from 14.52% quarter-on-quarter, even though it remained below 26.71% in the year-ago period.

Standalone numbers also showed higher operations income versus Q1 FY26 (₹315.93 crore vs ₹278.63 crore, as cited), but lower standalone PAT versus Q1 FY26 (₹40.53 crore vs ₹51.85 crore, as cited). On the consolidated side, the dataset explicitly stated consolidated PAT of ₹30.35 crore for Q1 FY27 compared with ₹40.19 crore in Q1 FY26 in one comparison set.

Analysis: how to read “recovery” versus “pressure”

The data supports two simultaneous takeaways. Revenue growth appears intact based on both the ₹327.20 crore consolidated operations income and the increase in standalone operations income cited versus the year-ago quarter. At the same time, the year-on-year decline in margin and profits points to cost pressure or mix changes during the period, consistent with the narrative that profitability declined year-on-year.

The sharp quarter-on-quarter improvement in EBITDA, PBT, and PAT in the summary suggests that Q4 FY26 was a weaker base and that operating performance improved in Q1 FY27. Investors typically look for confirmation in management commentary on what drove the sequential improvement, and whether the margin improvement can be sustained without relying on one-off items.

Given the pending land lease renewal flagged in the provided text, and the mention of investments in subsidiaries, the earnings call scheduled for August 3, 2026 becomes an important checkpoint for clarifications on operating expenses, subsidiary performance, and project timelines.

Conclusion

Archean Chemical’s Q1 FY27 results showed higher income and a clear sequential recovery in profitability metrics, but year-on-year margins and profits were still lower based on the disclosed comparisons. The company’s next detailed update is expected during its earnings conference call on August 3, 2026, following the board’s approval of the unaudited results on July 30, 2026.